Anixa's Ovarian Cancer CAR-T Trial Shows Extended Survival, Enables Major Dose Escalation
Event summary
- 12 patients treated in Phase 1 trial of lira-cel for recurrent ovarian cancer, with 7 exceeding expected median survival of 3-4 months.
- One patient survived 28 months post-treatment, three survived over a year.
- No dose-limiting toxicities observed, enabling dose escalation up to 100x higher under amended protocol.
- Next cohort to receive lymphodepletion regimen to potentially enhance CAR-T efficacy in solid tumors.
- Anixa to discuss trial updates in Water Tower Research fireside chat on February 10, 2026.
The big picture
Anixa's encouraging survival data in ovarian cancer represents a strategic validation of its CER-T technology platform. The ability to escalate doses significantly while maintaining a clean safety profile suggests potential differentiation in the challenging solid tumor CAR-T space. This trial's innovative approach to intra-peritoneal delivery and lymphodepletion positioning could influence broader solid tumor immunotherapy strategies if efficacy is demonstrated at higher doses.
What we're watching
- Therapeutic Efficacy
- Whether higher dose levels will demonstrate improved clinical outcomes in this difficult-to-treat patient population.
- Safety Profile
- How the absence of dose-limiting toxicities at current levels will translate as dosing escalates.
- Regulatory Pathway
- The pace at which Anixa can advance this program toward potential pivotal studies based on these early signals.
Related topics